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Abstract
Background: Recurrent Clostridium difficile infection (CDI) remains problematic, with up to 30 % of individuals
diagnosed with primary CDI experiencing at least one episode of recurrence. The success of microbial-based
therapeutics, such as fecal microbiota transplantation, for the treatment of recurrent CDI underscores the
importance of restoring the microbiota. However, few studies have looked at the microbial factors that contribute
to the development of recurrent disease. Here we compare microbial changes over time in patients with or
without recurrence to identify microbial signatures associated with the development of recurrence.
Methods: We used 16S rRNA-encoding gene sequence analysis to compare the fecal microbiota of 93 patients
with recurrent and nonrecurrent CDI, sampled longitudinally. Cross-group and intra-individual differences in
microbial community diversity and similarity were compared prior to the development of recurrent disease and
over time.
Results: Samples from these patient groups exhibited variable community profiles, clustering into four distinct
community groups. Cross-group comparison of the index sample collected from patients that did or did not
develop recurrence revealed differences in diversity and community structure (analysis of molecular variance,
p < 0.05). Intra-individual comparisons of the microbiota were more informative and samples from recurrent
patients were less likely to recover in diversity (Chi-square test, p < 0.005), exhibiting less community similarity
overall (Kruskal–Wallis test, p < 0.05). Interestingly, patients with severe disease harbored a significantly less diverse
community, a trend that was observed across both nonrecurrent and recurrent patient groups (Wilcoxon test, p < 0.05).
Conclusions: To date, this study represents one of the largest studies focused on the relationship between predictive
signals from the gut microbiota and the development of recurrent CDI. Our data demonstrate that specific
microbiota-derived characteristics associate with disease severity and recurrence and that future studies could
incorporate these characteristics into predictive models.
Background
Clostridium difficile infection (CDI) has become one of
the most prevalent hospital-acquired infections in recent
years [1]. Adding to the impact of CDI, recurrent disease
affects 20–30 % of patients after an initial diagnosis [2].
Although multiple factors are associated with recur-
rence, the exact contributions of these factors to the
development of recurrence in certain patients remain un-
determined. Strains of C. difficile belonging to the 027 ribo-
type have been associated with higher rates of recurrence at
some institutions [3]. Similarly, certain antibiotic treatment
options have also been associated with more recurrence [4].
Failure to develop an adaptive immune response against
the C. difficile toxins has also been associated with in-
creased risk for recurrence [5]. Since the relationship be-
tween the gastrointestinal microbiota, i.e., the indigenous
microbes of the gastrointestinal tract, and the development
of CDI has been well-established, specific differences in the
gastrointestinal microbiota may contribute to susceptibility
to recurrence.
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The importance of the gut microbiota in recovering from
a recurrent CDI cycle has been previously demonstrated.
Fecal microbiota transplantation (FMT) is one of the most
effective therapies for recurrent CDI, with an over 90 %
success rate [6–8]. Several studies have observed a signifi-
cant recovery in the diversity of the microbial community
following FMT, although the specific microbes that contrib-
ute to recovery are variable between patients [9–11]. How-
ever, studies have not followed CDI patients over time to
compare those that do or do not develop recurrent disease.
The objective of this study was to compare the gastro-
intestinal microbiota of patients diagnosed with CDI, with
or without recurrence. We examined the microbiota at ini-
tial diagnosis (index) time points, as well as the longitu-
dinal changes in the microbiota of patients over time. We
observed marked differences in the recovery of recurrent
patients compared with nonrecurrent cases. This study
represents the most comprehensive exploration of the
microbiota during development of recurrent CDI.
Methods
Study design, patient population, and sample collection
Fecal samples for this study were selected retrospect-
ively from a biorepository created as part of the NIH En-
terics Research Investigational Network (ERIN) study, and
encompassed patients who received care at the University
of Michigan Health System (UMHS) from October 2010
to June 2014. The ERIN study obtained the index fecal
specimens through collection of discarded fecal material
after C. difficile testing by the clinical microbiology labora-
tory and follow-up specimens through informed consent
of patients who were aged over 18 years and not pregnant.
Patients included in this study were selected based on the
availability of multiple fecal samples following an initial
CDI diagnosis (Fig. 1). The number of longitudinal sam-
ples varied between patients, as did the interval between
individual samples (Table 1; Additional file 1: Table S1).
Clinical data were extracted from the electronic med-
ical record through both automated query and manual
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Fig. 1 Study design and sample collection timeline. Relative timeline (days) of samples collected from patients diagnosed with initial Clostridium
difficile infection (CDI) (index sample = 0 days) categorized into three patient groups (nonrecurrent, recurrent, and reinfected). Patients who did not
develop recurrence (n = 42) remained free of a subsequent CDI diagnosis. Patients with recurrent disease (n = 32) were diagnosed with CDI
(positive clinical lab result) 14–56 days following index sample collection. Patients diagnosed with another CDI index outside of the recurrence
window (>56 days) were considered reinfected (n = 19) NA = test not available
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chart review by infectious disease clinicians (KR and
DM) (Additional file 1: Table S1).
Samples were collected in Cary-Blair transport media as
per hospital protocol during the study period. Clinical test-
ing for CDI was performed at the discretion of the patients’
inpatient care team, following institutional and national
guidelines that recommend testing of only symptomatic pa-
tients [12]. Testing for CDI in the clinical lab followed a
two-stage algorithm employing the C. diff Quik Chek
Complete (TechLab, Blacksburg, Virginia, USA), which de-
tects glutamate dehydrogenase (GDH) antigen and toxins
A and B via enzyme immunoassay, with confirmation by
polymerase chain reaction (PCR) for the C. difficile toxin
gene, tcdB, if the toxin and GDH results from the Quik
Chek test were discordant. The C. difficile clinical status
(“positive” or “negative”) used in this study is based on the
presence of a positive test and symptoms and is listed under
“clinical lab result” in Additional file 1: Table S1. Index, re-
current, and reinfected cases were defined in conjunction
with a positive Quik Chek result with a chart review con-
firming symptoms of CDI and the patient’s medical history.
The “sample status” definition used in Additional file 1:
Table S1 and Fig. 6 is based on the Infectious Diseases Soci-
ety of America (IDSA) surveillance definitions [13] applied
to each patient, resulting in categorization of the patient
into nonrecurrent, recurrent, or reinfected clinical groups
as follows: index (first positive sample collected in study),
recurrence (subsequent positive sample 15–56 days from a
previous positive sample), reinfection (subsequent positive
sample >56 days from a previous positive sample), treat-
ment (sample collected within 14 days of a positive sample,
during antibiotic treatment), and recovery (nonrecurrent,
non-reinfected sample collected >14 days from a positive
sample). Disease severity (based on the IDSA criteria of a
circulating white blood cell count >15,000 cells/mm3 and/
or a serum creatinine >1.5 times the baseline value) [12]
was recorded when available (Table 1; Additional file 1:
Table S1). Following routine testing in the clinical labora-
tory, excess sample was transported to the research labora-
tory and stored at −80 °C before further processing.
We isolated C. difficile from each sample as described
previously [14, 15]. Fecal samples were grown in taurochol-
ate cycloserine cefoxitin fructose agar (TCCFA) media an-
aerobically overnight to enrich for C. difficile spores, then
plated on TCCFA media to isolate single C. difficile col-
onies. The ribotypes of single C. difficile isolates were ob-
tained using a high-throughput ribotyping protocol,
previously validated at multiple centers [14]. Results from
these analyses are listed in Additional file 1: Table S1 under
“plating results” and “ribotype”.
DNA extraction and 16S rRNA sequencing
Total fecal DNA was extracted from 200–300 μl fecal con-
tent using the MoBio PowerMag soil isolation kit opti-
mized for the epMotion 5075 TMX (MoBio Laboratories,
#271004EP; Eppendorf) using the manufacturer’s instruc-
tions, which includes a mechanical bead-beating step. The
University of Michigan Host Microbiome core prepped
DNA libraries as previously described [16]. In brief, ampli-
fication of the 16S V4 region was accomplished using spe-
cific barcoded dual index primers as described in Kozich
et al. [17]. The PCR reaction included the following: 5 μl of
4 μM stock combined primer set, 0.15 μl of Accuprime
High-Fidelity Taq with 2 μl of 10× Accuprime PCR II buf-
fer (Life Technologies, #12346094), 11.85 μl of PCR-grade
water, and 1 μl of template. The PCR cycling conditions
were as follows: 95 °C for 2 minutes, 30 cycles of 95 °C for
20 s, 55 °C for 15 s, and 72 °C for 5 minutes, and 10 mi-
nutes at 72 °C. The DNA library plates were normalized
with a SequelPrep normalization kit (Life Technologies,
#A10510-01) and pooled. The pooled concentration was
quantified using the Kapa Biosystems Library Quantifica-
tion kit for Illumina platforms (KapaBiosystems, #KK4854)
and amplicon size was determined using the Agilent Bioa-
nalyzer high-sensitivity DNA analysis kit (#5067-4626).
The MiSeq Reagent 222 kit V2 (#MS-102-2003) was used
to sequence the amplicons (500 total cycles) with modifica-
tions for the primer set. Illumina’s protocol for library
preparation was used for 2 nM libraries, with a final load-
ing concentration of 4 pM spiked with 10 % PhiX for
Table 1 Patient and sample metadata
Patient group Number of
patients
(total n, %)
Number of samples
(total n, mean
n/patient, range)
Relative distance
to index sampling
(median days, range)
Age (years;
mean, range)
Sex (n, %) Number of
patients with
known IBD
(total n, %)
Number of patients
with known antibiotic
exposure prior to
CDI (total n, %)
Nonrecurrent 42 (66.3 %) 80, 2/patient
(1–4 samples)
8 (1–110) 57.7 (18–89) F: 18 (43 %)
M: 24 (57 %)
2 (5 %) 15 (36 %)
Recurrent 32 (19.4 %) 94, 3/patient
(1–6 samples)
42 (3–596) 53.9 (26–84) F: 22 (69 %)
M: 10 (31 %)
0 5 (15 %)
Reinfected 19 (14.3 %) 51, 3/patient
(1–7 samples)
134 (5–799) 56.4 (23–78) F: 10 (53 %)
M: 9 (47 %)
1 (5 %) 5 (26 %)
Total 93 225, 2.4/patient
(1–7 samples)
31 (1–799) 55.6 (18–89) F: 50 (54 %)
M: 43 (46 %)
3 (3 %) 25 (27 %)
The number of patients and samples per group, with age, sex, and relative distance to initial sampling per patient group. F female, M male
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diversity. Paired-end reads of FASTQ files for all samples
are available in the Sequence Read Archive under BioPro-
ject PRJNA307992 (SRP068473).
Data processing and analysis
Detailed commands for data processing, presentation,
and statistical analysis are available at https://github.-
com/aseekatz/ERIN.recurrence. Raw sequence files were
processed using mothur v1.34.4 [18]. Sequences were
trimmed, aligned, and binned, using UCHIME to remove
chimeric sequences [19]. A mothur-adapted version of the
SILVA rRNA database project (release v119) was used to
align the V4 region [20]. Samples with less than 1400 reads
were discarded. Sequences were taxonomically classified at
80 % bootstrap minimum using the Wang method to the
mothur-adapted RDP database (v10) [21]. Standard and
loadable R packages (R Foundation for Statistical Comput-
ing, Vienna, Austria, v3.1.0) were used to process the data
following processing in mothur. The Partitioning Around
Medoids (PAM) clustering algorithm was used to cluster
samples into community clusters based on the Jensen–
Shannon divergence from phylotype relative abundance in
R as conducted previously [22] using the silhouette score
to determine the optimal number of clusters (S(i) = 0.26,
four clusters). A 97 % cutoff was used to bin sequences
into operational taxonomic units (OTUs) in mothur for
downstream analyses. The inverse Simpson index (λ), the
Yue and Clayton dissimilarity index (θYC) [23], and princi-
pal coordinates analysis (PCoA) of θYC distance were cal-
culated in mothur using OTU abundance. Results were
plotted using R. A heatmap of the relative abundance of
dominant OTUs was visualized using the R package gplots
[24]. Standard R commands were used to visualize the re-
sults from linear discriminant analysis (LDA) effect size
(LEfSe) in nonrecurrent/recurrent patients or clinically
negative/positive samples [25].
Statistical analysis
Wilcoxon rank sum tests were used to determine signifi-
cance of binary group comparisons for diversity λ and
community dissimilarity θYC. The Kruskal–Wallis was used
for comparison of three or more groups. Analysis of mo-
lecular variance (AMOVA) was used to compare group
communities, as directed in mothur [26]. To compare di-
versity λ between nonrecurrent and recurrent patients, a
generalized estimating equation (GEE) model was applied
[27]. The R package “geepack” was used to calculate the
model, using a first order autoregressive correlation struc-
ture and a binomial link-logit family specification [28]. A
Chi-squared test was performed to determine distribution
of sample categories in the four identified microbial com-
munity type clusters and for inference about the variable
coefficients’ point estimates from GEE.
Results
Distinct microbial community features are present in the
feces of patients with severe C. difficile infection but are
not with recurrent infection
Following an initial diagnosis of CDI (index sample),
longitudinal fecal samples were collected from patients
with nonrecurrent and recurrent disease and patients
who were reinfected with C. difficile past the 56-day
window of the recurrence definition, as described in
“Methods” (Fig. 1, Table 1). The fecal microbiota from
each sample was examined by 16S rRNA-encoding gene
sequence analysis.
To determine the microbial community membership and
investigate shared similarities or differences within the fecal
microbiota of patients with or without recurrence or reinfec-
tion, we examined the phylotypes, or genus-level taxonomic
classification, of the microbial community. We employed a
previously used method, Partitioning Around Medoids
(PAM), clustering on the taxonomic classification of phylo-
types to identify distinct community clusters [22, 29]. Inves-
tigation of the community membership in samples from all
patient groups revealed variable community profiles and
dominance by specific organisms as represented by OTUs
in patient samples (Fig. 2). Clustering (mean S(i)= 0.26) of
all samples resulted in four major community clusters
(Fig. 2): a high-diversity cluster defined by a high
relative abundance of one of two Proteobacteria
members (cluster 1); a cluster of samples rich in Bac-
teroidetes (cluster 3); and two low-diversity clusters
characterized by Enterococcus (cluster 4) or an En-
terobacteriaceae OTU (cluster 2).
Cluster 2 contained a disproportionate amount of sam-
ples from nonrecurrent, recurrent, and reinfected samples
compared with clusters 3 and 4 (Chi-square, p < 0.05); how-
ever, comparison of the proportion of index samples from
each patient within the patient groups was not significant.
When comparing the proportion of samples that were
negative or positive for C. difficile using clinical lab results,
none of the clusters was significantly disproportionate.
However, when using cultivation to determine C. difficile
status, cluster 4 contained a disproportionate amount of
negative samples compared with clusters 2 and 3 (Chi-
square, p < 0.05). Interestingly, samples during a severe
diagnosis were also significantly overrepresented in cluster
4 compared with cluster 3 (Chi-square, p < 0.05).
In addition to clustering samples by overall community
membership, we identified differentially abundant OTUs
using linear discriminant analysis (LDA) effect size (LEfSe)
[25]. LEfSe revealed five differentially represented OTUs in
samples that were positive or negative for C. difficile based
on University of Michigan Health System clinical lab results
(n = 204; Fig. 3a). One of these OTUs, OTU12, classified to
Clostridium XI, which includes C. difficile. While Clostrid-
ium XI can include other clostridial species in addition to C.
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difficile, this was the only differentially abundant OTU iden-
tified when the index (initial) samples from recurrent and
nonrecurrent patients was compared using LEfSe (n = 93),
suggesting a higher burden of Clostridium XI, potentially
C. difficile, is detectable in recurrent patients at initial diag-
nosis (Additional file 2: Figure S1). LEfSe comparison of
samples from patients with severe or non-severe disease at
initial disease (using only index samples for which a sever-
ity score was available, n = 86) revealed seven differentially
abundant OTUs with little overlap between differentially
abundant OTUs between positive and negative samples
(Fig. 3b). This suggests that within samples positive for C.
Fig. 2 Samples clustered into four major community profiles. The relative abundance of the 40 most abundant operational taxonomic units (OTUs),
with classification to the genus level and organized by bacterial phylum, is shown in columns. Samples were binned into four major clusters using the
Partitioning Around Medoids (PAM) algorithm based on the Jensen–Shannon divergence. The mean inverse Simpson index (λ) per cluster is shown on
the left axis (samples). Sample categorization on the left axis is based on the following classifications: patient group category (nonrecurrent, recurrent,
or reinfected); clinical lab results (Quik Chek, positive or negative); C. difficile cultivation results (positive or negative); and disease severity (severe or
non-severe) at sample collection during a CDI diagnosis NA = text result not available
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difficile, patient metadata such as severity may be corre-
lated to several different community structures.
Microbial diversity at initial CDI diagnosis is decreased in
patients with severe or recurrent disease
The diversity of the fecal microbiota community in the ini-
tial sample at diagnosis collected from nonrecurrent, recur-
rent, and reinfected patients was compared by calculating
the inverse Simpson index (λ; n= 42, n = 32, n = 19, respect-
ively). There was no difference in diversity when patients
were classified based on clinical lab results (negative or posi-
tive for C. difficile), antibiotic exposure prior to initial diag-
nosis, or prior CDI history (Additional file 3: Figure S2).
However, the fecal microbiota at initial diagnosis (index
sample) in patients with recurrence trended towards a
lower diversity compared with patients with nonrecur-
rent disease (Fig. 4a; Kruskal–Wallis test, p = 0.10).
Furthermore, samples collected from patients with se-
vere disease at diagnosis had lower fecal microbiota
diversity compared with those without severe disease
(Fig. 4b; Wilcoxon test, p = 0.022). Comparison of samples
collected during severe or non-severe disease within the
nonrecurrent, recurrent, and reinfected patient groups
followed a similar trend; patients with severe CDI at the
time of sample collection within each group exhibited
lower diversity (Additional file 3: Figure S2).
Investigation of the microbiota diversity over time within
each of the patient groups revealed time-dependent differ-
ences between patients with or without recurrence. To ac-
count for the inherent correlation present in repeated
measures data, we utilized a generalized estimating equa-
tion (GEE) model to examine whether diversity (λ) was in-
creased in nonrecurrent patients over time compared with
recurrent patients. In this model, both time and repeated
sampling are accounted for. We found that diversity and
sampling across time were correlated in nonrecurrent pa-
tients, suggesting that as diversity increases across sam-
pling time, recurrence is less likely to occur (p < 0.0013).
In patients with recurrent disease and patients reinfected
with C. difficile, no such increase in diversity across time
was observed, suggesting that individual recovery of diver-
sity is distinct in nonrecurrent patients compared with re-
current patients.
The fecal microbiota community is more dynamic within
patients without recurrence
To investigate the inter- and intra-individual similarities of
the fecal community within the patients and their groups,
we calculated the beta diversity using the Yue and Clayton
distance (θYC), a measure of similarity that accounts for
abundance [23]. Principal coordinates analysis (PCoA)
based on the θYC revealed significant differences between
samples from recurrent, nonrecurrent, and reinfected pa-
tients using analysis of molecular variance (AMOVA)
(Fig. 5a; p < 0.016) [26]. Comparison of the index samples
(initial sample) from each patient category also trended
towards being significantly different (Additional file 4: Figure
S3; p < 0.068). We also observed significant differences be-
tween samples that tested positive or negative for C. difficile
based on clinical results (Fig. 5b; p < 0.015) and using culti-
vation (Additional file 4: Figure S3; p < 0.001). A biplot of
the correlating OTUs towards PCoA axes 1 and 2 revealed
four OTUs responsible for opposing directions of the
PCoA-determined communities: OTU4 (classified as Escher-
ichia), OTU2 (classified as Enterococcus), and OTU3/OTU4
(both classified as Bacteroides) (Fig. 5).
We next investigated how intra-individual similarity
changed over time. We observed that all of the longitu-
dinal samples collected from a given recurrent patient
were more similar (θYC, comparing only intra-individual
samples) compared with the longitudinal samples from a
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Fig. 3 Differentially abundant members of the microbiota in patients
with C. difficile infection. The mean relative abundance plus standard
error (se) of differentially abundant operational taxonomic units (OTUs)
identified by linear discriminant analysis (LDA) effect size (LEfSe) in
(a) samples that tested positive or negative for C. difficile by the
clinical laboratory (Quik Chek) or (b) severe or non-severe samples.
OTUs that were overrepresented in the specified groups are color-coded
by the respective group in each panel
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nonrecurrent or reinfected patient (Fig. 6a; Kruskal–
Wallis, p < 0.025). We compared the community dissimi-
larity θYC within each patient throughout consecutive
sampling. Sequential comparison of changes throughout
time did not reveal major differences between recurrent
and nonrecurrent patients (Additional file 5: Figure S4).
However, consecutive sampling does not necessarily take
into account the variability in each patient’s clinical his-
tory, such as a change from index sampling (initial diag-
nosis) to subsequent recovery (negative for C. difficile)
or recurrence (a second positive). To account for the
variability in the clinical status of the patient throughout
sampling, we annotated each sample status to reflect the
patient medical history as follows: index, recurrence, re-
infection, treatment, recovery (see “Methods” section for
detailed definitions) (Additional file 1: Table S1). We ob-
served greater intra-individual similarity within the recur-
rent group when a patient’s index sample was compared
with another recurrence or reinfection, as well as recovery
or treatment. Nonrecurrent patients were more likely to
exhibit more dissimilarity, suggesting changes in the mi-
crobial community, during recovery and treatment phases.
Discussion
This study represents one of the first longitudinal studies
focused on the role of the microbiota in the development
of recurrent CDI. Cross-sectional studies comparing the
fecal microbiota of diarrheal patients with or without CDI
at diagnosis with that of healthy controls have observed a
range of community types, with variable community mem-
bers associated with CDI [30, 31]. It is possible that incorp-
oration of other CDI considerations, such as severity or
recurrence, can impact the identification of community
members that may exacerbate disease. Combined with the
inherent variability already present in the human micro-
biota [22, 32], generalizing all patients with CDI in one
group is not ideal. Indeed, studies in murine models suggest
that multiple community types from different antibiotic
treatments are susceptible to C. difficile, suggesting that dis-
ease development, and the development of recurrence, is
variable and complex [33–35]. As illustrated by our data,
both severity and the development of recurrence were asso-
ciated with decreased diversity and community resilience.
Similarly, the fecal microbiota in patients with recurrent
CDI prior to fecal microbiota transplantation (FMT) has
been observed to be variable, albeit severely decreased in
diversity [9, 10]. The study presented here attempted to dis-
sect some of these variables within a patient population that
already does not possess a healthy microbiota.
Previous studies have used results from the clinical la-
boratory to determine the C. difficile status of a patient
[30, 36, 37]. Our current study identified differentially
represented OTUs as well as differential community
structure between samples positive or negative for C.
difficile based on the clinical laboratory test used at our
hospital (C. diff Quik Chek), and cultivation of C. diffi-
cile from these samples generally agreed with testing re-
sults. We were unable to isolate C. difficile from samples
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Fig. 4 Fecal microbial diversity during initial C. difficile infection. The inverse Simpson index (λ) of the microbiota in (a) index samples
collected at initial C. difficile infection (CDI) diagnosis in nonrecurrent (n = 42), recurrent (n = 32), and reinfected (n = 19) patients
(Kruskal–Wallis, not significant (ns)) and (b) index samples from patients diagnosed with severe (n = 36) or non-severe (n = 50) CDI
(Wilcoxon test, p = 0.022)
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during the standard antibiotic treatment window (14
days following a positive sample), potentially due to re-
sidual antibiotics in the sample. Overall, the abundance
of Clostridium XI identified via 16S rRNA-based sequen-
cing did not correlate with a positive test from the clin-
ical lab or cultivation efforts. However, OTU12, belonging
to Clostridium XI, was the only overrepresented OTU in
the index sample of recurrent patients compared with
nonrecurrent patients, suggesting that abundance of C.
difficile is potentially important in the development of
recurrence.
Differences in the fecal microbiota at index sampling
within recurrent, nonrecurrent, and reinfected patients
were less pronounced compared with differences between
C. difficile negative or positive samples. A previous small
study demonstrated that patients with recurrent disease
have a less diverse community than patients with nonrecur-
rent CDI [38]. We did observe a slightly lower diversity in
the index samples from patients with recurrence and re-
infection patients compared with the index sample from pa-
tients without recurrence. However, we did find that intra-
individual changes over time were more informative. Both
diversity over time and overall community dissimilarity in-
creased in patients without recurrence, suggesting that the
microbial community in these patients is more dynamic.
The similarity in the microbial community of samples col-
lected during “index” and “treatment” time points in nonre-
current patients was variable, suggesting dynamic changes
in the community regardless of the test results. In contrast,
there was greater similarity between samples collected dur-
ing “recurrence”, “treatment”, “recovery”, or “reinfection” in
patients who developed recurrence. Community types that
are less susceptible to recurrence might be very individual
and rely on the ability of the microbiota to change rather
than the microbiota sharing a feature with that of other re-
current patients.
Surprisingly, we also observed significant differences
in microbial diversity between samples collected during
severe disease or not. Although LEfSe analysis revealed
seven differentially present OTUs between severe and
non-severe samples, few OTUs overlapped with LEfSe
comparisons of C. difficile negative and positive samples.
Comparison of patient samples categorized by severity
within each of the patient groups (recurrent, nonrecur-
rent, or reinfected) each followed similar trends, suggest-
ing that severity and recurrence were not associated. The
severity score used in our study [12] does not reflect ser-
ious complications such as pseudomembranous colitis,
ileus/toxic megacolon, or sepsis. However, it does suggest
that other physiological parameters may be associated
with changes in the gut microbiota and this severity score
is frequently positive early in the disease process, when
our index samples were collected. Given that in-
creased gut microbiota diversity is associated with re-
covery from recurrent CDI following FMT, a simple
severity score may be of value when deciding on
treatment. Recent application of FMT for the treat-
ment of severe disease has been effective in prevent-
ing later recurrence [39, 40]. If overall diversity of a
community is in part predictive of susceptibility to re-
currence, preemptive measures to promote recovery
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Fig. 5 Community structure of patients with or without recurrent C.
difficile infection. Principal coordinates analysis (PCoA) was used to
plot the Yue and Clayton dissimilarity index (θYC). a The community
structure of the microbiota in samples from nonrecurrent, recurrent,
and reinfected patients (analysis of molecular variance (AMOVA),
p = 0.016). b The community structure of samples positive or
negative for C. difficile as determined by the clinical lab using
Quik Chek (AMOVA, p = 0.015)
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of diversity may be especially important in this pa-
tient population.
We were unable to identify a single microbiota-based
metric that would predict the development of recurrent
CDI. However, longitudinal analysis that considers the
individual’s potential for recovery implied that patients
with a more dynamic fecal microbiota were less likely to
develop recurrence. This warrants analysis in a larger,
more structured study to understand how recovery can be
managed to decrease the likelihood of a recurrent episode
and to better characterize the role of microbiota-derived
variables in predictive models of severity/recurrence. As
we gain a better understanding of the microbiota and their
functions, which may include activities such as bile acid
metabolism [35, 41], we may be in a position to identify
patients at increased risk of recurrent disease and inter-
vene through therapies that are designed to restore neces-
sary microbiome functions.
Conclusions
We observed distinct differences in microbiota diversity of
patients with CDI that did or did not develop recurrent
disease. Both static and longitudinal analysis indicated that
recovery of the microbiota community is different in
recurrent patients, suggesting that the overall microbiota
structure may be important in susceptibility to recurrence.
Additionally, disease severity at the time of diagnosis may
be associated with the status of a patient’s fecal microbiota
diversity. Validation of our observations in a larger cohort
of patients that do or do not develop recurrence could aid
in identification of microbial determinants that are associ-
ated with developing recurrent CDI.
Ethics approval and consent to participate
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tion of data processing and generation of all figures and
statistics are available at https://github.com/aseekatz/
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Additional files
Additional file 1: Table S1. Sample description and metadata. The
relative abundance of the top 100 operational taxonomic units (OTUs),
with taxonomic classification, for all samples is listed in columns.
Metadata for each sample is described across each row. (XLSX 236 kb)
Additional file 2: Figure S1. Relative abundance of distinct community
members in patient groups. The mean relative abundance plus standard
error (se) of operational taxonomic units (OTUs) identified by linear
discriminant analysis (LDA) effect size (LEfSe) in C. difficile-positive and
-negative samples was plotted in nonrecurrent, recurrent, and reinfected
patients. LEfSe analysis identified OTU12 (Clostridium XI) was also
overrepresented in index samples of recurrent patients compared with
nonrecurrent patients. (PDF 118 kb)
Additional file 3: Figure S2. Comparison of diversity in the fecal
microbiota in patients with C. difficile infection (CDI). Comparison of
the microbial diversity (inverse Simpson index λ) in a severe and
non-severe samples in nonrecurrent, recurrent, and reinfected patients
(Kruskal–Wallis test, p = 0.040), b C. difficile positive versus negative samples
(not significant), c patients with or without prior antibiotic exposure
(not significant) and d with or without a history of prior CDI (not
significant). (PDF 173 kb)
Additional file 4: Figure S3. Community structure of patients with or
without recurrent C. difficile infection. Principal coordinates analysis
(PCoA) was used to plot the Yue and Clayton dissimilarity index (θYC). a
The community structure of the microbiota in index (initial) samples from
nonrecurrent, recurrent, and reinfected patients (analysis of molecular
variance (AMOVA), p = 0.068). b The community structure of samples
positive or negative for C. difficile as determined by cultivation (AMOVA,
p = 0.001). (PDF 166 kb)
Additional file 5: Figure S4. Intra-individual similarity of the microbiota
in patients with or without recurrent C. difficile infection over sequential
sampling. The microbial community similarity over sequential time within
nonrecurrent and recurrent patients was compared using the Yue and Clayton
dissimilarity index (θYC; Wilcoxon test, not significant). (PDF 102 kb)
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